Lung cancer in young nonsmokers is on the rise: Uncovering the cause
March 12, 2021
- American Society of Clinical Oncology
- American Society of Hematology
- Association of VA Hematology/Oncology
- Dallas County Medical Society
- Texas Medical Association
Jonathan Dowell, M.D.
Chief of Hematology & Oncology, Dallas VA Medical Center
- Internal Medicine - Hematology/Oncology
- Non-Small Cell and Small Cell Lung Cancers
- Mesothelioma
New Patient Appointment Accepting Virtual Visits or 214-645-4673
Biography
Jonathan E. Dowell, M.D., is a Professor in the Department of Internal Medicine at UT Southwestern Medical Center. He specializes in lung cancer, mesothelioma, and thymic malignancies. He is also Chief of the Section of Hematology and Oncology at the Dallas Veterans Affairs Medical Center.
Dr. Dowell earned his medical degree at the University of Chicago Pritzker School of Medicine. He completed a residency in internal medicine at UT Southwestern Medical Center and gained advanced training through a hematology and oncology fellowship at Vanderbilt University Medical Center.
Certified by the American Board of Internal Medicine in hematology and oncology, he joined the UT Southwestern faculty in 2000.
Passionate about medical education, Dr. Dowell is the Education Director for UT Southwestern’s Division of Hematology and Oncology and is the Subspecialty Education Co-Coordinator for Hematology and Oncology for the Internal Medicine Residency Program.
He is Chair of the Simmons Cancer Center Data and Safety Monitoring Committee and a member of the Clinical Cancer Research Committee at UT Southwestern. At the VA Medical Center, he is Co-Chair of the Cancer Committee and the Transfusion Utilization Committee.
On the national level, Dr. Dowell is a member of the National Comprehensive Cancer Network’s committees for Non-Small Cell Lung Cancer, Thymomic Malignancies, and Mesothelioma. He is also active in several professional societies, including the American Society of Clinical Oncology, the American Society of Hematology, the Texas Medical Association, and the Dallas County Medical Society.
Dr. Dowell’s research focuses on thoracic malignancies. His investigations have resulted in more than 60 publications in peer-reviewed journals and contributions to more than 35 book chapters, reviews, editorials, and case reports. Additionally, he has presented his findings at scientific conferences throughout the United States and internationally.
He is also an ad hoc reviewer for a host of journals, including Journal of Clinical Oncology, Cancer Investigation, Expert Opinion on Oncology, and Journal of Thoracic Diseases.
Personal Note
When he’s not at work, Dr. Dowell enjoys travel, baseball, and family activities.
Education & Training
- Internship - UT Southwestern Medical Center (1993-1994), Internal Medicine
- Residency - UT Southwestern Medical Center (1994-1996), Internal Medicine
- Medical School - University of Chicago Pritzker School of Medicine (1989-1993)
- Fellowship - Vanderbilt University Medical Center (1997-2000), Hematology Oncology
Professional Associations & Affiliations
Honors & Awards
- Best Doctor, 2012, 2018-2023, D Magazine
Books & Publications
-
Books
-
Small cell lung cancer: diagnosis, treatment, and natural history in Fishman’s Pulmonary Diseases and Disorders (6th ed.)
Dowell JE, Drapkin BJ, Gerber DE, Johnson DH (2023), New York, NY, McGraw Hill -
Mesothelioma in Lung Cancer
Dowell JE (2013), Oxford, UK, Oxford University Press -
Unknown primary in Prognosis in Cancer
Dowell JE (2008), Oxford, UK, Oxford University Press -
Clinical and biologic implications of EGFR mutations in lung cancer in Lung Cancer Principles and Practice
Dowell J, Gazdar AF, Shigematsu H, Herz J Minna JD (2005), Philadelphia, PA, Lippincott, Williams and Wilkins
-
Small cell lung cancer: diagnosis, treatment, and natural history in Fishman’s Pulmonary Diseases and Disorders (6th ed.)
-
Publications
-
Upper Extremity Venous Thrombosis in Patients With Cancer With Peripherally Inserted Central Venous Catheters: A Retrospective Analysis of Risk Factors
Ahn DH, Illum HB, Wang DH, Sharma A, and Dowell JE Journal of Oncology Practice 2013 5 -
A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.
Dowell JE, Dunphy FR, Taub RN, Gerber DE, Ngov L, Yan J, Xie Y, Kindler HL Lung cancer (Amsterdam, Netherlands) 2012 Sep 77 3 567-71 -
Consent timing and experience: modifiable factors that may influence interest in clinical research.
Gerber DE, Rasco DW, Skinner CS, Dowell JE, Yan J, Sayne JR, Xie Y Journal of oncology practice / American Society of Clinical Oncology 2012 Mar 8 2 91-6 -
ERCC1 expression and outcomes in head and neck cancer treated with concurrent cisplatin and radiation.
Hayes M, Lan C, Yan J, Xie Y, Gray T, Amirkhan RH, Dowell JE Anticancer research 2011 Dec 31 12 4135-9 -
Predictors and impact of second-line chemotherapy for advanced non-small cell lung cancer in the United States: real-world considerations for maintenance therapy.
Gerber DE, Rasco DW, Le P, Yan J, Dowell JE, Xie Y Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011 Feb 6 2 365-71 -
Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population.
Rasco DW, Yan J, Xie Y, Dowell JE, Gerber DE Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010 Oct 5 10 1529-35 -
Small cell lung cancer: are we making progress?
Dowell JE The American journal of the medical sciences 2010 Jan 339 1 68-76 -
The impact of consenter characteristics and experience on patient interest in clinical research.
Rasco DW, Xie Y, Yan J, Sayne JR, Skinner CS, Dowell JE, Gerber DE The oncologist 2009 May 14 5 468-75 -
Small-cell lung cancer: translational research enroute to therapeutic advances.
Dowell J, Minna JD Oncology (Williston Park, N.Y.) 2008 Nov 22 13 1493, 1495 -
Phase 1/2 dose escalating study of twice-monthly pemetrexed and gemcitabine in patients with advanced cancer and non-small cell lung cancer.
Dudek AZ, Larson T, McCleod MJ, Schneider DJ, Dowell JE, Banerjee TK, Pandya KJ, Bromund JL, Chen R, Monberg MJ, Obasaju CK Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008 Apr 3 4 394-9 -
A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871.
Lewis LD, Miller AA, Rosner GL, Dowell JE, Valdivieso M, Relling MV, Egorin MJ, Bies RR, Hollis DR, Levine EG, Otterson GA, Millard F, Ratain MJ Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Jun 13 11 3302-11
-
Upper Extremity Venous Thrombosis in Patients With Cancer With Peripherally Inserted Central Venous Catheters: A Retrospective Analysis of Risk Factors
Research
- Thoracic malignancies
Clinical Focus
- Non-Small Cell and Small Cell Lung Cancers
- Mesothelioma
- Thymic Malignancies
Results: 1 Locations
Lung, Head, and Neck Cancer Clinic
at Cancer Care Outpatient Building 6202 Harry Hines Blvd., 9th FloorDallas, Texas 75235 (214) 645-4673 Directions to Lung, Head, and Neck Cancer Clinic at Cancer Care Outpatient Building, Dallas Parking Info for Lung, Head, and Neck Cancer Clinic
New Patient Appointment Accepting Virtual Visits or 214-645-4673